A new early-stage study suggests that injecting one tumor triggered a whole-body cancer response in some patients with metastatic disease. Researchers tested a redesigned CD40 agonist antibody, 2141-V11, and delivered it directly into a tumor rather than through the bloodstream. In a phase 1 trial involving 12 patients, tumors shrank in 6 patients, and 2 patients entered complete remission.
What made the result stand out was not only the shrinkage in the injected tumors. Researchers also saw tumors in other parts of the body shrink or disappear, even though those sites never received the drug directly. That kind of body-wide response is rare in local cancer treatment and suggests the therapy may help the immune system recognize and attack cancer more broadly.
Why Earlier CD40 Drugs Fell Short
Scientists have studied CD40 agonist antibodies for more than two decades because CD40 helps activate immune cells and can strengthen anti-tumor responses. But earlier versions of these drugs brought disappointing results in people. Clinical trials showed limited benefits, and the treatments often caused severe side effects, including widespread inflammation, low platelet counts, and liver damage.
The team at Rockefeller University, led by Jeffrey V. Ravetch, sought to solve both problems simultaneously. In earlier preclinical work, they redesigned the antibody to bind human CD40 more effectively and to improve crosslinking through a specific Fc receptor interaction. Lab studies suggested the new version was about 10 times more effective at triggering an immune attack against tumors.
They also changed how doctors delivered it. Instead of using intravenous infusion, which exposes healthy tissues across the body to the drug, the researchers injected the antibody directly into tumors. That approach appears to have sharply reduced toxicity. Ravetch said the team saw only mild toxicity with local injection.
Two Complete Remissions Drew Particular Attention
The trial included patients with several forms of metastatic cancer, including melanoma, renal cell carcinoma, and different types of breast cancer. None of the participants experienced the severe side effects linked to earlier CD40 drugs. Six patients showed tumor shrinkage throughout the body, and two saw all detectable cancer disappear.
The two complete responses involved melanoma and metastatic breast cancer, both diseases known for aggressive spread and recurrence risk. In one case, Ravetch said doctors repeatedly injected a single tumor in a patient’s thigh, and tumors elsewhere on her leg and foot disappeared. In the breast cancer case, doctors injected only a skin tumor, yet tumors in the skin, liver, and lung also vanished.
The Drug May Turn Tumors Into Immune Hotspots
Samples taken from treated tumors showed the extent of the immune response. Researchers found large numbers of immune cells inside tumors, including dendritic cells, T cells, and mature B cells. These cells formed clusters resembling lymph nodes, known as tertiary lymphoid structures. Scientists often link those structures to better cancer outcomes and stronger immunotherapy responses.
Researchers also detected these immune structures in tumors that had not been injected with the cells. That finding may help explain why injecting one tumor triggered a whole-body cancer response in some patients. Once the immune system identified the cancer, immune cells appeared to migrate to other tumor sites and continue the attack.
Larger Trials Will Test Who Benefits Most
The results remain early, and the study was small. Still, the findings have already led to larger phase 1 and phase 2 trials involving nearly 200 patients. Those studies are testing 2141-V11 in harder-to-treat cancers, including bladder cancer, prostate cancer, and glioblastoma. Researchers want to learn why some patients respond while others do not and whether they can predict response before treatment begins.
The early trial also offered one possible clue. The two patients whose cancer disappeared both showed high T-cell clonality at the start of treatment, suggesting certain immune-system features may matter. The team’s next goal is to identify those markers more clearly. The study was published in Cancer Cell, and its authors say the long-term challenge now is not just improving the therapy, but learning how to turn more non-responders into responders.